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We have previously reported on the deregulation of cellular microRNAs involved in hematopoiesis and inflammation
in human T-cell lymphotropic virus type 1 (HTLV-I)–transformed cells. In this study, we demonstrate that miR-150 and
miR-223 specifically target the signal transducer and activator of transcription 1 (STAT1) 3′ untranslated region, reducing
STAT1 expression anddampening STAT1-dependent signaling in human T cells. The effects ofmiR-150 andmiR-223 on
endogenous STAT1 were confirmed using inducible cell lines. Our studies also showed that miR-150 expression
is upregulatedby interleukin-2 signaling in adult T cell leukemia/lymphoma (ATL) cells. HTLV-I–transformedandATL-derived
cells have reduced levels of miR150 and miR223 expression, which coincide with increased STAT1 expression and
STAT1-dependent signaling. Knockdown of STAT1 by short hairpin RNA demonstrated that the constitutive activation
of STAT1 is required for the continuous proliferation of HTLV-I–transformed cells. Our studies further demonstrate that
increased expression of STAT1 in ATL cells is associatedwith higher levels ofmajor histocompatibility complex class I
expression. Previous studies have demonstrated that the pressure exerted by natural killer (NK) cells in vivo can edit
leukemic tumor cells by forcing an increased expressionofmajor histocompatibility complex class I to escape immune
clearance. STAT1-expressing tumor cells produce more aggressive tumors because they cannot be eliminated by NK
cells. Our results suggest that therapeutic approaches using combined targeting of STAT1 andMHC class I may be an
effective approach to activate NK cell–mediated clearance of ATL tumor cells.
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MicroRNAs (miRNAs) are involved in a wide range of biologic
processes, including cellular survival, differentiation, immune
response, and oncogenesis. miRNAs are short non-coding RNAs
that target genes through imperfect base pairing with mRNAs,
thereby affecting their stability and/or their translation. An individual
miRNA has numerous cellular gene targets and the manner in which
to accomplish a coordinated regulation of biologic processes is
unclear. The role of miR-150 in human cancer is context-dependent
as this miRNA can have either oncogenic or tumor suppressor activity
in cells that originate from different tissues. This is best illustrated by
upregulated expression of miR-150 in CD19+ B cells from chronic
lymphocytic leukemia (CLL) [1,2] but downregulated expression in
chronic myeloid leukemia [3,4], acute lymphoblastic leukemia [5], and
mantle cell lymphoma [6]. Additional studies have further demonstrated
that miR-150 stimulates the proliferation and migration of lung cancer
cells by targeting SRC kinase signaling inhibitor 1 (SRCIN1) and SRC
activity [7]. In contrast, in situ hybridization revealed that miR-150expression levels are reduced in both estrogen receptors positive and
triple-negative breast cancer samples compared to adjacent normal cells,
andmiR-150 expressionwas shown to inhibit breast cancer cell migration
and invasion [8,9]. Some of the known validated cellular gene targets of
miR-150 include c-MYB, NOTCH3, CBL, EGR2, AKT2, and DKC1
Table 1. Predicted miRNA Target Sites of Human STAT1
miRNAs Total Sites 8mer 7mer-m8 7mer-1A Aggregate Probability of Conserved Targeting
miR-223 2 1 0 1 0.27
miR-150 1 0 0 1 0.14
miR-144 1 1 0 0 b0.1
miR-130ac 1 0 0 1 b0.1
miR-155 1 0 0 1 b0.1
miR-140 1 0 1 0 b0.1
miR-203 1 1 0 0 b0.1
miR-27abc 1 0 0 1 b0.1
miR-200bc 1 0 0 1 b0.1
miR-101 1 0 0 1 b0.1
miR-146ac 1 0 1 0 b0.1
miR-132 1 0 0 1 b0.1
miR-26ab 1 0 0 1 b0.1
450 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015[10–14]. Similar to miR-150, miR-223 is also differentially regulated.
Studies showed that it is frequently repressed in hepatocellular carcinoma
[15], B-CLL [16], acute myeloid leukemia (AML) [17], gastric
mucosa-associated lymphoid tissue lymphoma [18], and recurrent
ovarian cancer [19]. In contrast, miR-223 is upregulated in T cell acute
lymphocytic leukemia (T-ALL) [20], EBV-positive diffuse large B-cell
lymphoma [21], and metastatic gastric cancer [22,23]. Among validated
cellular gene targets of miR-223 are FBXW7/Cdc4, RhoB, stathmin 1,
E2F transcription factor 1 (E2F1), signal transducer and activator of
transcription 3 (STAT3), CCAAT/enhancer binding protein beta,
forkhead box O1, and nuclear factor I/A [22–27].
Human T-cell lymphotropic virus type 1 (HTLV-I) is a human
retrovirus present in 20 million people worldwide [28]. Infection with
HTLV-I is the etiological agent of adult T cell leukemia/lymphoma
(ATL) [29] and a neurodegenerative disease called tropical spastic
paraparesis/HTLV-I–associated myelopathy [30,31]. Only a few
studies have investigated miRNA expression in HTLV-I–mediated
T cell transformation and pathogenesis [32–37]. HTLV-I–associated
disease pathogenesis is still poorly understood [38–40]. Both diseases
originate from deregulated proliferation of infected CD4/CD25+
T cells.While it is unclear how the virus induces cellular transformation,
the viral oncoprotein Tax plays an essential role and is sufficient to
immortalize human primary T cells [41]. Tax expression leads to
accumulation of DNA double-strand breaks during cellular replication
and simultaneously targets DNA repair pathways to increase genetic
instability [42,43]. In addition, Tax targets many tumor suppressors,
cell cycle regulators, and survival factors and affects chromosome
stability and segregation [44–48]. The molecular events linked to the
switch from immortalization [interleukin-2 (IL-2)–dependent growth]
to transformation (IL-2–independent growth) are largely unknown. A
common characteristic found in HTLV-I–transformed cells in vivo and
in vitro is the constitutive activation of the Janus activated kinase (JAK)/
STAT signaling [49,50]. In fact, pharmacological targeting of the JAK/
STAT axis has shown that activation of this pathway is required for
continuous proliferation and survival of HTLV-I–transformed cells
[51–53]. STAT1 plays a role in immune modulatory functions,
anti-viral responses, apoptosis, and anti-proliferative responses [54]. In
contrast, several studies have shown that STAT1 can also act as a potent
tumor promoter for leukemia development [55] and that many T-ALL
leukemic cells are dependent on the TYK2-STAT1-BCL2 pathway for
continued survival [56]. However, a potential role played by STAT1 in
HTLV-I pathogenesis has not yet been investigated.
In this study, we demonstrate for the first time that miRNAs miR-150
and miR-223 directly target the STAT1 3′ untranslated region (UTR)
gene. Expression of both miR-150 and miR-223 was significantly reducedin HTLV-I–transformed cell lines and ATL-derived cells, while STAT1
protein expression was elevated. Restoring miR-150 and miR-223
expression inhibited endogenous STAT1 expression and the activation of
STAT1 transcription–dependent genes and significantly reduced the
proliferation of HTLV-I–transformed cells and ATL cells. A direct role of
STAT1 on cell cycle and expansion ofHTLV-I cells was further confirmed
by using short hairpin RNA (shRNA) targeting STAT1. We also found
that IL-2–dependent ATL cell lines express higher levels of miR-150,
suggesting that IL-2 signaling may be involved in the transcriptional
up-regulation of miR-150 expression. Finally, we found that a majority of
freshly isolated uncultured ATL samples have high expression of STAT1,
which correlated with higher major histocompatibility complex class I
(MHC-I) expression and may help to conceal ATL cells against immune
clearance by natural killer (NK) cells.
Experimental Procedure
miRNA Target Predictions
STAT1 sequences were obtained from the National Center for
Biotechnology Information Nucleotide database (http://www.ncbi.
nlm.nih.gov/). Sequences of mature human miRNAs were obtained
from the miRNA Registry at miRBase (http://www.mirbase.org). The
prediction algorithms Targetscan and PicTar were used to search for
miRNA target sites in the human STAT1 3′UTR.
Cell Culture and Patient Samples
A 293T cell line was cultured in complete Dulbecco's modified
Eagle's medium with 10% FBS, penicillin, and streptomycin. The
HTLV-I cell lines, MT-4, MT-2, C8166, C91PL, and human T cell
lymphoblast cell line, Jurkat, were maintained in RPMI-1640
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS, penicil-
lin, and streptomycin. The ATL-like cell lines, MT-1, ATL-T,
ED-40515(−), ALT-25, ATL-43T, LMY1, and ATL-55T, were
maintained in RPMI-1640 supplemented with 10% FBS, penicillin,
and streptomycin and IL-2 (50 U/ml) as needed [57–59]. Patient
samples were obtained after informed consent was provided and in
agreement with regulations for the protection of human subjects
according to the National Institutes of Health guidelines. RNA was
extracted from peripheral bloodmononuclear cells (PBMCs) of patients
with acute ATL and healthy donors (HD). RNA was extracted from
PBMCs of patients with ATL.Plasmids
Precursors of miR-150 and miR-223 were cloned in pTRIPZ.
pTRIPZ lentivirus is an inducible vector engineered to be Tet-On.
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Figure 1. STAT1 is a direct target of miRNA miR-150. (A) A diagram representing the sequence alignment of miR-150 and its target site
within STAT1 3′UTR and the relative mutated version. The mutations made in the STAT1 3′UTR are highlighted. (B) Real-time PCR was
performed on mature miR-150 from cDNA derived from 293T cells transfected with pcDNA or miR-150. Real-time PCR was performed in
duplicate, and samples were normalized to RNU6b (U6) expression. (C) 293T cells were cotransfected with wild-type (or mutated) STAT1
3′UTR luciferase reporter plasmids and pTK–Renilla luciferase plasmids, together with a control plasmid (pcDNA) or a different amount of
miR-150 (0.125, 0.25, 0.75 μg). After 48 hours, firefly luciferase activity was measured and normalized by Renilla luciferase activity. The
data are representative from two independent experiments. (D) Real-time PCR of STAT1 expression was performed from total cDNA from
293T cells transfected with pcDNA or miR-150 (2 μg). Extracts were analyzed 48 hours after transfection and normalized to GAPDH
expression. P value was b .05. (E) Western blot analysis of STAT1 expression from total cellular extracts of 293T cells infected with
lentivirus expressing miR-150 or empty lentivirus used as a control. Extracts were normalized to actin expression. Semiquantitative
analysis of Western blot data demonstrated 24.9% inhibition of STAT1 expression by miR-150. Western blot quantification was
performed by using the Java-based image processing program ImageJ.
Neoplasia Vol. 17, No. 5, 2015 miR-150 and miR-223 target STAT1 Moles et al. 451pTRIPZ contains puromycin resistance that was used to select a stable
cell line. The stable cell lines derived were incubated in the absence or
presence of doxycycline and subjected to reverse transcription–polymerase
chain reaction (RT-PCR) to analyze miR-150 and miR-223 expression.
Precursors of miR-150 and miR-223 were also cloned in the pSIH1-green
fluorescent protein (GFP) lentivirus and pcDNA vector. shRNA against
STAT1 was cloned in the pSIH1-GFP vector.
3′UTR and Luciferase Reporter Assay
The full-length 3′UTR of the human STAT1 gene was cloned into
the luciferase vector, pGL3 (Promega). STAT1 3′UTR containing the
mutated miR-150 target sequence and the mutated miR-223 target
sequence were generated by QuikChange Site-Directed Mutagenesis
kit (Stratagene). miR-150 and miR-223 were cloned into the pcDNA
expression vector. 293T cells were cotransfected using Polyfect
Transfection reagent (Qiagen), with 300 ng of the indicated luciferase
reporter plasmid, 200 ng of pRL-TK–Renilla luciferase plasmid
(Promega, for normalization), and the indicated miRNAs (125, 250,
500, or 750 ng). Cell extracts were prepared 48 hours after
transfection. Cell extracts were lysed in 1× passive lysis buffer(Promega) and analyzed using the Luciferase Reporter Assay System
(Promega), according to the manufacturer’s instructions. Luciferase
assays were performed twice from independent experiments, and data
were normalized for transfection efficiency using Renilla luciferase
activity. 293T cells were cotransfected with 300 ng of the STAT1
luciferase reporter plasmid, 200 ng of pRL-TK–Renilla luciferase, and
the indicated miRNAs. Cell extracts were prepared 48 hours after
transfection according to the manufacturer’s instructions.
293T cells were stimulatedwith 500pg/ml human interferon-γ (IFN-γ;
PBL Assay Science, Piscataway, NJ) or 100 U/ml human IFN-β (ProSpec,
East Brunswick, NJ) and cotransfected with 300 ng of pISRE-TA-Luc
Vector, 200 ng of pRL-TK–Renilla luciferase plasmid, and 500 ng of the
indicated miRNAs by using Polyfect. Cell extracts were prepared 48 hours
after transfection and luciferase assays were performed as described above.
Transfection, Viruses, and Generation of Stable miR-150 and
miR-223 Inducible Cell Lines
293T cells were infected with lentiviral particles expressing
miR-150 and miR-223. Lentiviruses were prepared by transfection
of 293T cells with 10 μg of pSIH1-miR-150, pSIH1-miR-223,
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Figure 2. STAT1 is a direct target of miRNA miR-223. (A) The diagrams represent the sequence alignment of miR-223 and its target sites
within the STAT1 3′UTR and the relative mutated versions. The mutations made in the STAT1 3′UTR are highlighted. (B) Real-time PCR
was performed on mature miR-223 from cDNA derived from 293T cells transfected with pcDNA or miR-223. Real-time PCR was
performed in duplicate, and samples were normalized to RNU6b (U6) expression. (C, D) 293T cells were cotransfected with wild-type (or
mutated) STAT1 3′UTR firefly luciferase reporter plasmids and pTK–Renilla luciferase plasmids, together with a control plasmid (pcDNA)
or miR-223. After 48 hours, firefly luciferase activity was measured and normalized to Renilla luciferase activity. The data are
representative from two independent experiments. (E) Real-time PCR of STAT1 expression was performed from total cDNA from 293T
cells transfected with pcDNA or miR-223 (2 μg). Extracts were analyzed 48 hours after transfection and normalized to GAPDH expression.
Western blot analysis of STAT1 expression from total cellular extracts of 293T cells infected with lentivirus expressing miR-223 or empty
lentivirus used as a control is also shown. Extracts were normalized to actin expression. miR-223 demonstrated a 38.1% inhibition of
STAT1 expression. Western blot quantification was performed by using the Java-based image processing program ImageJ.
452 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015pTRIPz/miR-150, or pTRIPz/miR-223, 5 μg of vesicular stomatitis
virus G proteins, and 5 μg of pDNL6 using calcium phosphate
(Invitrogen). The virus was collected in the supernatant for 4 days,
concentrated by ultracentrifugation, and resuspended in phosphate-
buffered saline. For inducible miR-150 and miR-223 expression
assays, MT-4 or Jurkat cells were infected with lentiviruses encoding
vector control (pTRIPz), miR-150 (pTRIPz/miR-150), or miR-223
(pTRIPz/miR-223). Cells were selected with 10 μg/ml puromycin for
12 days. Stable cell lines derived were incubated in the absence or
presence of doxycycline and subjected to RT-PCR to analyze
miR-150 and miR-223 expression.
RNA Extraction and Real-Time Quantitative PCR
RNA was extracted using TRIzol (Invitrogen) and treated with
DNaseI (Roche Applied Science, Indianapolis, IN). RNA was
reverse-transcribed using the RNA-to-cDNA synthesis kit (Applied
Biosystems, Carlsbad, CA). Quantitative real-time PCR was
performed using Real-Time SYBR Green PCR Master Mix(SABiosciences, Valencia, CA) on the StepOnePlus Real-Time PCR
System (Applied Biosystems), with glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression as an internal control. The
miScript II RT Kit was used for mature miRNA quantification.
cDNA generated with the miScript II RT Kit was used as a template
for real-time PCR to detect the expressive level of mature miR-150
and miR-223 in HTLV-I and ATL cell lines. Real-time PCR was
performed in duplicate, and samples were normalized to RNU6b
(U6) expression.
Western Blot Analysis
Cells were washed with phosphate-buffered saline and lysed in
RIPA buffer with phosphatase and protease inhibitors (Complete
Cocktail; Roche). Protein concentration was determined with the
Bio-Rad protein assay (Bio-Rad, Hercules, CA). Total protein
extracts were resolved by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, transferred to Immobilon polyvinylidene difluoride
membranes (Millipore, Darmstadt, Germany), and probed with
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Figure 3. miR-150 and miR-223 hamper the IFN-mediated response by inhibition of STAT1 activity. (A) 293T cells stimulated with 500 pg/ml
human IFN-γ and co-transfected with the pISRE firefly luciferase reporter plasmid and pTK–Renilla luciferase plasmid, together with a control
plasmid (pcDNA),miR-150,miR-223, and/or STAT1 cDNAexpressing vector lacking the 3′UTR sequence. After 48 hours, firefly luciferase activity
was measured and normalized by Renilla luciferase activity. The data are representative from two independent experiments. (B) 293T cells
stimulated with 100U/ml human IFN-β and co-transfected with the pISRE firefly luciferase reporter plasmid and pTK–Renilla luciferase plasmid,
together with a control plasmid (pcDNA), miR-150,miR-223, and/or STAT1 cDNA expressing vector lacking the 3′UTR sequence. After 48 hours,
firefly luciferase activity was measured and normalized by Renilla luciferase activity. The data are representative from two independent
experiments. (C) 293T cells were cotransfected with STAT1-luciferase reporter plasmid and pTK–Renilla luciferase plasmid, together with a
control plasmid (pcDNA), miR-150, miR-223, or STAT1 cDNA expressing vector. (D) 293T cells were cotransfected with wild-type STAT1 3′UTR
firefly luciferase reporter plasmid and pTK–Renilla luciferase plasmids, together with a control plasmid (pcDNA), miR-150, and/or miR-223. After
48 hours, firefly luciferase activity was measured and normalized by Renilla luciferase activity. (E) 293T cells transfected with pcDNA, mir-150,
and/or mir-223 (1 μg) and 50 ng of pSIH1-puromycin. Forty-eight hours after transfection, the cells were treated with puromycin (1 μg/ml) for
7 days. Western blot analyses of STAT1 expression from total cellular extracts were performed. Extracts were normalized to actin expression.
Semiquantitative analysis of Western blot data shows 9.7% and 9% inhibition of STAT1 expression by mir-150 and mir-223, respectively,
compared to the control. Co-transfection of mir-150 and mir-223 demonstrate 23% inhibition of STAT1 expression. Western blot quantification
was performed by using the Java-based image processing program ImageJ.
Neoplasia Vol. 17, No. 5, 2015 miR-150 and miR-223 target STAT1 Moles et al. 453STAT1 (Cell Signaling Technology, Danvers, MA) and Bcl2, p21,
p27, or actin (Santa Cruz Biotechnology, Santa Cruz, CA) antibodies.
Western blot quantification was performed by using the Java-based
image processing program ImageJ (http://imagej.nih.gov/ij/).
Results
miRNAs miR-150 and miR-223 Target the STAT1 3′UTR
The prediction algorithms Targetscan and PicTar were used to
identify common gene targets to miRNAs downregulated in
HTLV-I–transformed cells. Among potential targets, STAT1
appeared as a possible target and was selected for further analyses
(Table 1). We identified a 7-mer-1A binding site for miR-150 in
position 426-432nt of the STAT1 3′UTR (Figure 1A). To
demonstrate a direct effect of miR-150 on STAT1 mRNA, the
full-length (1667 bp) STAT1 3′UTR was cloned into a pGL-3
reporter luciferase construct and miR-150 was cloned into thepcDNA expression vector. First, we verified the transfection of the
mature miR-150 by using RT-PCR (Figure 1B). Expression of the
STAT1 3′UTR vector along with a different amount of miR-150
demonstrated a 50% inhibition of luciferase activity (Figure 1C ). To
further demonstrate specificity, we performed site-directed mutagen-
esis to modify the seed sequence and generate a mutated STAT1 3′
UTR vector (Figure 1A). As expected, miR-150 had no significant
effect on the mutated STAT1 3′UTR construct (Figure 1C ). These
results demonstrated a specific and direct effect of miR-150 on the
STAT1 3′UTR. We next wanted to validate these results on the
endogenous STAT1 gene. To this end, we expressed in 293T cells the
pSIH1-miR-150 or pSIH1-GFP control vector. Our results
confirmed the effect of miR-150 on the endogenous STAT1 gene
at both the RNA and the protein levels (Figure 1, D and E ). The
down-regulation was not as efficient as seen with the 3′UTR
luciferase experiment because in the latter experiment the transfection
efficiency limits the percentage of cells in which an effect can be
454 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015observed. We then investigated the effect of miR-223. The STAT1 3′
UTR sequence displays two miR-223 target sites positioned at
970-977nt and 1194-1200nt (Figure 2A). We verified the transfection
of the mature miR-223 by using RT-PCR (Figure 2B). To investigate if
one site was more important than the other, we mutagenized each site
independently (mutant-UTR 970 and mutant-UTR 1194; Figure 2A).
These mutants were tested along with wild-type STAT1 3′UTR in
transient assays. Results indicated that mutation of a single site had no
effect and miR-223 was still able to repress activity from the STAT1 3′
UTR (Figure 2C ). However, when both sites were simultaneously
mutated, miR-223 was no longer able to suppress the activity of the
STAT1 3′UTR, suggesting that the effect of miR-223 is specific and
requires only one functional binding site (Figure 2D). We next validated
these results on the endogenous STAT1 gene.We expressed in 293T cells
the pSIH1-miR-223 or pSIH1-GFP control vector and analyzed by
RT-PCR andWestern blot. Results confirmed the effect of miR-223 on
the endogenous STAT1 gene, which was observed at the protein level
(Figure 2E ). RT-PCR analysis shows no significant change in STAT1
expression (Figure 2E ). That result suggested that miR-223 regulated
STAT1 expression at a post-transcriptional level.
miR-150 and miR-223 Decrease STAT1 Protein Expression
and STAT1 Signaling
STAT1 is a transcription factor involved in inflammation and
cancer. STAT1 is a central mediator of the IFN responses involved in
antiviral and immune defense [60]. Since miR-150 and miR-223
target STAT1, we hypothesized that these miRNAs may hamper the
IFN-mediated response by dampening STAT1 activity. To test this
hypothesis, we first used the ISRE reporter construct plasmid
containing four tandem repeats of the IFN-inducible response
element. As expected, IFN-γ and IFN-β treatment resulted in the
induction of ISRE-luciferase reporter gene activity. Expression of
either miR-150 or miR-223 resulted in significant inhibition, which
was efficiently rescued by co-expression of a STAT1 cDNA
expression vector lacking the 3′UTR sequence (Figure 3, A and B).
IFN-independent, STAT1-dependent signaling was also inhibited byFigure 4.miR-150andmiR-223expressioncorrelateswithSTAT1express
maturemiR-150andmiR-223 fromcDNAderived fromHTLV-I–transforme
lines (MT-1,ATL-T, ED-40515(−), andATL-25). Thenon–HTLV-I Jurkat T ce
and samples were normalized to RNU6b (U6) expression. Fold change
expression. (B, E) Real-time PCR was performed on STAT1 from cDNA
performed in duplicate, and samples were normalized to GAPDH e
Jurkat-normalized STAT1 expression. P values were b .05. (C, F) Western
extracts of Jurkat, HTLV-I, andATL cell lines. Extractswere normalized to
165%, 158%, and 131% increase in STAT1 expression inMT-4,MT-2, and
STAT1 in MT-1, ATL-T, ED-40515(−), and ATL-25, respectively, compare
Java-based image processing program ImageJ. (G) Real-time PCR was
ATL-derived, IL-2–dependent cell lines (LMY1, 55-T, 43T). The non–HTLV-
in duplicate, and samples were normalized to RNU6b (U6) expression. (
ATL-derived, IL-2–dependent cell lines (LMY1, 55-T, 43T). Real-time PC
expression. (I)Western blot analysis of STAT1 expressionwas performed
Extracts were normalized to actin expression. Semiquantitative analysis o
expression in LMY1, ATL-55T, and ATL-43T, respectively, compared
Java-based imageprocessingprogram ImageJ. (J)Real-timePCRwasper
(LMY1, 55-T, 43T) cultured with and without IL-2 for 48 hours. Fold chan
linesculturedwith IL-2. (J) Real-timePCRwasperformedonmaturemiR-1
with andwithout IL-2 for 48 hours. Fold changewas calculated by compar
blot analysis of STAT1 expressionwas performed from total cellular extra
Extracts were normalized to actin expression. Semiquantitative analysis
expression in MT-1 and ATL-T cell lines, respectively, cultured with IL-2.miR-150 and miR-223 as demonstrated by a reduction in
STAT1-luciferase reporter construct activity when transfected along
with miR-150 or miR-223, which was efficiently rescued by
co-expression of a STAT1 cDNA expression vector lacking the 3′
UTR sequence (Figure 3C ). An additive effect of miR-150 and
miR-223 was demonstrated in transient transfection inhibition of the
STAT1-3′UTR construct (Figure 3D). Finally, Western blot analysis
demonstrated that STAT1 expression is reduced more efficiently by
the co-transfection of miR-150 and miR-223 (Figure 3E ).
miR-150 and miR-223 Expression Is Inversely Correlated
With STAT1 Expression in HTLV-I–Transformed and ATL
Cell Lines
We next investigated the expression of miR-150 and miR-223 in
relation to STAT1 in HTLV-I–transformed cell lines (MT-4, MT-2,
and C8166). Jurkat cells were used as a negative control since Jurkat cells
are human T cells not transformed with HTLV-I. In HTLV-I–
transformed cell lines, the expression of bothmiR-150 andmiR-223was
significantly reduced when compared to Jurkat cells (Figure 4A). In
contrast, the expression of STAT1 was increased at both the RNA and
the protein levels (Figure 4, B and C ). We then investigated if such a
correlation could also be found in ATL-derived cell lines (MT-1, ATL-T,
ED-40515(−), ATL-25). Results from these studies confirmed that both
miRNAs, miR-150 and miR-223, were significantly downregulated
when compared to Jurkat cells (Figure 4D). Consistent with the above
data, STAT1 RNA and protein expression was also increased in ATL
cells (Figure 4, E and F ). These results suggest an inverse correlation
between miR-150 or miR-223 and STAT1 expression in HTLV-I–
transformed and ATL-derived cells in vitro. Surprisingly, we found that
IL-2–dependent ATL-derived cells (ATL-43T and ATL-55T) displayed
elevated levels of miR-150 but not miR-223 (Figure 4G ), suggesting
that the formermay be regulated through the IL-2 signaling pathway. To
further investigate this possibility, we withdrew the IL-2 from the culture
media of ATL–IL-2–dependent cells and analyzed the expression of
miR-150 after 48 hours. Our results suggest that the absence of IL-2
signaling in ATL cells may be associated with decreased expression ofion inHTLV-I andATLcell lines. (A,D)Real-timePCRwasperformedon
dcells (MT-4,MT-2, andC8166) andATL-derived IL-2–independent cell
ll linewasusedasacontrol. Real-timePCRwasperformed in duplicate,
was calculated by comparing values with Jurkat normalized miRNA
derived from HTLV-I cell lines and ATL cell lines. Real-time PCR was
xpression. Fold change was calculated by comparing values with
blot analysis of STAT1 expression was performed from total cellular
actin expression. Semiquantitative analysis ofWestern blot data shows
C8166, respectively, and 178%, 195%, 166%, and 148%activation of
d to Jurkat. Western blot quantification was performed by using the
performed on mature miR-150 and miR-223 from cDNA derived from
I Jurkat T cell line was used as a control. Real-time PCRwas performed
H) Real-time PCR was performed on STAT1 from cDNA derived from
R was performed in duplicate, and data were normalized to GAPDH
from total cellular extracts of Jurkat andATL–IL-2–dependent cell lines.
fWestern blot data shows 225%, 188%, and 162% increase in STAT1
to Jurkat. Western blot quantification was performed by using the
formedonmaturemiR-150 fromATL-derived, IL-2–dependent cell lines
ge was calculated by comparing values with LMY1, 55-T, and 43T cell
50 fromATL-derived, IL-2–independent cell lines (MT-1,ATL-T) cultured
ing valueswithMT-1, ATL-T cell lines culturedwithout IL-2. (K)Western
cts ofMT-1, ATL-T cell lines culturedwith andwithout IL-2 for 48 hours.
of Western blot data shows 50.8% and 67.7% inhibition of STAT1
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456 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015miR-150 (Figure 4J ). To validate the results, we cultured ATL–IL-2–
independent cell lines (MT-1, ATL-T) in the presence of IL-2 and
analyzed the expression of miR-150 after 48 hours. Our results show that
IL-2 signaling is associatedwith a significant increase inmiR-150 (Figure 4J ).
Next, we analyzed STAT1 expression. The absence of IL-2 signaling in
ATL–IL-2–dependent cells is not correlated with an increase in STAT1
expression (data not shown). Interestingly, IL-2 stimulation in MT-1 and
ATL-T cells resulted in STAT1 down-regulation (Figure 4K ). These results
may be significant because several studies have reported that in vivo
ATL tumor cells can produce IL-2 or IL-15 and express the high
affinity IL-2 receptor α chain, CD25. We think that these
observations may, in part, explain the higher levels of miR-150
found in freshly isolated uncultured ATL cells compared to in vitro
cell lines. Despite higher expression of miR-150 in IL-2–dependent
cell lines, STAT1 RNA and protein were expressed at higher levels
compared to Jurkat cells (Figure 4, H and I ).
Enforced Expression of miR-150 and miR-223 in Human
T Cells Decreases STAT1 Expression and STAT1-Dependent
Transcription
To further demonstrate the effect of miR-150 and miR-223
expression on STAT1, we constructed miR-150 and miR-223
Tet-inducible expression vectors. These vectors were used to generate
stable cell lines expressing pTRIPZ (control line), pTRIPZ-miR-150,or pTRIPZ-miR-223 in HTLV-I–transformed MT-4 cells. Treat-
ment with doxycycline for 3 days efficiently restored expression of
miR-150 or miR-223 in MT-4 cells (Figure 5A). In Jurkat T cells,
induction of miR-223 was more limited. We believe that this is the
result of saturation because Jurkat cells naturally express high levels of
endogenous miR-223 (Figure 6A). Induction of miR-150 and
miR-223 expression was associated with down-regulation of
endogenous STAT1 expression (Figures 5B and 6B). Notably, we
also confirmed that expression of several STAT1-dependent genes,
MAP/microtubule affinity-regulating kinase 3 (MARK3), inositol
monophosphatase domain containing 1 (IMPAD1), and SET
binding protein 1 (SETBP1) [61], in the absence of IFN stimulation,
was suppressed after induction of miR-150 and miR-223 (Figures 5,
C–E, and 6, C–E ). Similar results were obtained in both MT-4 and
Jurkat cells. The effects were generally more pronounced in Jurkat
and we believe that this may reflect the fact that these genes are also
transcriptionally regulated by nuclear factor of kappa light polypep-
tide gene enhancer in B-cells, which is constitutively activated in
MT-4 cells. SETBP1 was not studied after miR-223 overexpression
because the 3′UTR for SETBP1 contains a putative miR-223 target
site (data not shown). Overall, these results demonstrate that under
physiological conditions miR-150 and miR-223 can reduce STAT1
expression and STAT1-dependent signaling in human leukemic T
cell lines.
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Transformed and ATL Cells
STAT1 expression has been frequently associated with the
increased expression of genes with anti-proliferative properties, such
as p21WAF or p27KIP [62]. We find no correlation between
STAT1, p21WAF, or p27KIP expression in HTLV-I and ATL cell
lines (Figure 9E ). However, some reports also suggest that increased
expression of STAT1 can contribute to rather than inhibit
transformation and proliferation of breast cancer, head and neck
cancer, melanoma, lymphoma, and leukemia cells [63]. Hence, the
role of STAT1 in different cancer types may depend on other genetic
alterations and other signaling pathways activated or not in these cells.
To evaluate the biologic significance of STAT1 in HTLV-I–
transformed cells, we first used MT-4 and MT-4 miR-150 and
miR-223 inducible cell lines. Induction of either miR-150 or
miR-223 expression was associated with reduced cell proliferation
as determined by cell count and 2,3-bis-(2-methoxy-4-nitro- 5-
sulfophenyl)-2H-tetrazolium- 5-carboxanilide (XTT) assays (Figure 7,
A and B). In T-ALL, STAT1 has been shown to activate Bcl2 and
promote proliferation and survival of transformed cells [64].
Consistent with these reports, we found that STAT1 was involvedin Bcl2 expression in MT-4 and Jurkat inducible cell lines
(Figure 7D). Treatment with doxycycline for 3 days significantly
increased Bcl2 expression compared to untreated cells (Figure 7C ).
For this reason, we analyzed Bcl2 expression in treated MT-4
miR-150, MT-4 miR-223, Jurkat-miR-150, and Jurkat-miR-223
cells compared to the treated MT-4 and Jurkat control. As expected,
the induction significantly decreased Bcl2 expression inMT-4 and Jurkat cell
lines (Figure 7D). To verify the specificity of these results, we included
Western blot analysis of untreatedMT-4 and Jurkat inducible cell lines. The
results show no change or an increased level of Bcl2 expression compared to
the control (Figure 7D). Because many T-ALL leukemic cells are dependent
on the TYK2-STAT1-BCL2 pathway for continued survival, we analyzed
the sequence of Tyk2 in several ATL samples. However, no mutation was
found in the kinase domain ofTyk2 inATL samples, but a high frequency of
Tyk2 V362F single nucleotide polymorphism was found. The possible
significance of this mutation remains to be established.
We are aware that miR-150 and miR-223 likely exert some of their
effect through STAT1-independent pathways. To demonstrate a
direct function of STAT1 in HTLV-I–transformed cells, we next
generated a lentiviral vector expressing shRNA to knock down
STAT1 expression. Functionality was first verified following infection
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458 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015of 293T cells (Figure 8, A and B). shRNA STAT1 efficiently reduced
STAT1 and Bcl2 expression (Figure 8B). We confirmed a reduction
in STAT1 expression in the HTLV-I–transformed MT-2 transduced
cells by more than 50% (Figure 8C ), which was associated with a
disruption in cell cycle progression, a 24.3% reduction in the number
of cells in S phase and an accumulation of cells in G2/M (Figure 8D).
To confirm that these observations were not specific to MT-2 and
could be generalized to other HTLV-I–transformed cells, we
transduced MT-2, C91PL, and MT-4 HTLV-I–transformed cells
and an MT-1 ATL cell line. Transduction of STAT1 shRNA was first
confirmed by using RT-PCR (Figure 9A). STAT1 down-regulation
was associated with reduced cell proliferation as determined by cell
count, XTT assays, and bromodeoxyuridine incorporation (Figure 9,
B–D). Together our results demonstrate that STAT1 is required for
the proliferation of HTLV-I–transformed and ATL cells.
Increased STAT1 and MHC-I Expression in ATL Cells
Since our results demonstrate an important role of STAT1 in
proliferation of HTLV-I–transformed cells, we then wanted to
investigate expression of STAT1 in freshly isolated uncultured ATL
samples. We next analyzed RNA samples from 35 patients with acute
ATL and 9 HDs by RT-PCR. Our results showed that STAT1 was
significantly elevated in patients with ATL compared with HD (almost
three-fold higher; Figure 10A). Early studies suggest that ATL cellsoriginate within the helper-inducer T cell subtype and have a common
cytokine production profile including IL-1α, IL-1β, tumour necrosis
factor alpha, IFN-γ, and granulocyte-macrophage colony-stimulating-
factor [65]. Among these factors, IFN-γ is a well-known potent inducer
of MHC class I through activation of the JAK/STAT1/interferon
regulatory factor 1 signal transduction pathway [66]. Tumor cells with
low or no MHC-I cell surface expression may escape recognition by
anti-tumor T cells but are highly sensitive to NK-mediated killing. In
fact, increased expression of MHC-I is one important mechanism that
allows for immune escape [67–70].We then investigated the expression
of MHC-I in ATL and HD samples. Overall, ATL samples have
significantly higher expression of MHC-I when compared to HD
samples (Figure 10B).
Discussion
In this study, we demonstrate for the first time that miR-150 and
miR-223 target the STAT1 3′UTR, reduce STAT1 expression, and
reduce both IFN-dependent and IFN-independent STAT1-mediated
signaling. We have previously reported that miR-150 and miR-223
are differentially regulated in HTLV-I cells transformed in vitro and
in vivo ATL samples, suggesting that ATL cells and in vitro
established HTLV-I cell lines may derive from distinct cellular
populations. In this study, we have shown that IL-2R–mediated
signaling can increase miR-150 expression in ATL cells. Previous
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460 miR-150 and miR-223 target STAT1 Moles et al. Neoplasia Vol. 17, No. 5, 2015studies have demonstrated that ATL cells overexpress an IL-2Rα
chain (CD25). Additional studies have shown that ATL cells may
produce or respond to IL-2 or other IL-2Rγ chain user cytokines in
the microenvironment [71–75]. In contrast, in vitro transformed cells
do express CD25 but do not produce IL-2. With regard to miR-223,
it has been previously shown that E2F1 represses the miR-223
promoter [26,76]. Interestingly, viral HTLV-I bZIP factor mRNA
increases the expression and transcriptional activity of E2F1 [77]. In
contrast to other viral genes, HTLV-I bZIP factor expression is
consistently increased in ATL cells in vivo [77]. These observations
can, in part, explain the differential regulation of miR-223 expression
between in vitro and in vivo HTLV-I–transformed cells. Others have
shown that overexpression of miR-150 in bone marrow progenitor
cells resulted in modest inhibition of cell proliferation [3], suggesting
low side effects. Therefore, reinstating miR-150 expression may
provide an effective therapeutic strategy to treat HTLV-I leukemia.
Our studies also revealed that STAT1 expression is inversely
correlated to that of miR-150 and miR-223 in HTLV-I–transformed
and ATL cells and is generally increased in HTLV-I–transformed
cells. Several studies have shown that an increase in STAT1
expression is associated with radio-protection of cancer cells. Since
HTLV-I–transformed cells are notoriously resistant to high dose
radiotherapy, it is possible that increased STAT1 expression plays arole in the resistance to high dose radiotherapy and warrants
additional studies. STAT1 has been associated with both tumor
suppressor and tumor promoting activities [78,79]. Our studies
suggest that in HTLV-I–infected cells STAT1 has a tumor promoting
effect since inhibition of STAT1 expression and STAT1-dependent
transcription through miR-150 or miR-223 or directly by shRNA
targeting resulted in reduced proliferation of HTLV-I–transformed
and ATL cells. In addition, STAT1 may play an important role in the
immune-suppressive status observed in patients with ATL and allow
HTLV-I–transformed cells to evade NK-mediated killing. Along
these lines, knockout mice studies showed that the IFN-α receptor 1
and STAT1 are both required for normal tumor Treg frequencies and
the release of IL-10, a potent inhibitor of NK activity, in the tumor
microenvironment. Indeed, high levels of IL-10 in the serum of
patients with acute ATL have been reported. Furthermore, increased
STAT1 as observed in patients with ATL may be involved in higher
levels of MHC-I expression. Although MHC-I is not a direct target
for STAT1, previous studies have demonstrated that STAT1 plays an
essential role in chromatin decondensation of the MHC locus
through interactions with the remodeling brahma protein-like 1
factor [80]. As indicated above, increased expression of MHC-I on
tumor cells has been associated with escape from NK-mediated killing
of tumor cells and more aggressive tumor phenotypes [81,82]. Our
results showed that patients with ATL with a higher expression of
STAT1 displayed higher levels of MHC-I as well. Since STAT1 plays
an important role in regulation of inducible nitric oxide synthase
activity, it is possible that it participates in upregulated expression of
inducible nitric oxide synthase in ATL cells.
There are also some unforeseen observations in our study. First,
suppressor of cytokine signaling 1, a terminator of STAT1-dependent
signaling, has been reported to be activated in HTLV-I–transformed
cells through a mechanism involving the Tax oncoprotein [83].
However, it should be remembered here that in vivo about half of
ATL samples have no detectable Tax expression [84], and therefore,
the ability of suppressor of cytokine signaling 1 to block STAT1 may
vary greatly among patients and is currently under investigation. In
addition, several kinases, including cyclin-dependent kinase 8, can
phosphorylate STAT1 at serine 727 to restrain NK cell cytotoxicity
by reducing expression of perforin and granzyme B [85]. Targeted
inhibition of cyclin-dependent kinase 8-mediated STAT1 phosphor-
ylation at serine 727 may represent a possible approach to stimulate
NK cell–mediated tumor surveillance in patients with ATL.
Despite expression of both miR-150 and miR-223 in freshly
isolated ATL samples, STAT1 did not seem to be affected, as both
STAT1 RNA and protein were increased in a majority of ATL
samples. These data suggest that in ATL patient cells miR-150 and
miR-223 may not be able to efficiently target the STAT1 3′UTR.
Although the reason for this deficiency is unclear, it is possible that
other higher affinity gene targets expressed at higher levels act as
competitors and sequester miR-150 and miR-223 or that the
sequence or the spatial structure/folding of the STAT1 3′UTR is
altered in ATL cells in vivo and warrants additional future studies.
Targeted inhibition of STAT1 has been investigated in various
types of leukemia. For instance, treatment of acute myeloid cells
(AML) with retinoic acid resulted in an increased STAT1 expression
and reduced proliferation [80]. In addition, STAT1 has been shown
to play a key role in dasatinib-induced differentiation of acute
myeloid cells (AML) and in Bryostatin-1–induced differentiation of
CLL cells [61,86]. The results presented here suggest that STAT1
Neoplasia Vol. 17, No. 5, 2015 miR-150 and miR-223 target STAT1 Moles et al. 461may represent a target for therapeutic intervention in some patients
with ATL.
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